Prostate cancer reactivates developmental epigenomic programs during metastatic progression-Reference-Cited by-同舟云学术

Prostate cancer reactivates developmental epigenomic programs during metastatic progression

Published:2020-07-20 Issue:8 Volume:52 Page:790-799
ISSN:1061-4036
Container-title:Nature Genetics
language:en
Short-container-title:Nat Genet

Author:

Pomerantz Mark M.,Qiu Xintao^ORCID,Zhu Yanyun,Takeda David Y.,Pan Wenting,Baca Sylvan C.,Gusev Alexander^ORCID,Korthauer Keegan D.,Severson Tesa M.,Ha Gavin^ORCID,Viswanathan Srinivas R.,Seo Ji-Heui,Nguyen Holly M.,Zhang Baohui,Pasaniuc Bogdan,Giambartolomei Claudia^ORCID,Alaiwi Sarah A.,Bell Connor A.,O’Connor Edward P.,Chabot Matthew S.,Stillman David R.,Lis Rosina,Font-Tello Alba^ORCID,Li Lewyn,Cejas Paloma,Bergman Andries M.,Sanders Joyce,van der Poel Henk G.,Gayther Simon A.^ORCID,Lawrenson Kate,Fonseca Marcos A. S.,Reddy Jessica,Corona Rosario I.,Martovetsky Gleb,Egan Brian^ORCID,Choueiri Toni^ORCID,Ellis Leigh^ORCID,Garraway Isla P.,Lee Gwo-Shu Mary,Corey Eva^ORCID,Long Henry W.^ORCID,Zwart Wilbert^ORCID,Freedman Matthew L.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Genetics

Link

http://www.nature.com/articles/s41588-020-0664-8.pdf

Reference97 articles.

1. Baca, S. C. et al. Punctuated evolution of prostate cancer genomes. Cell 153, 666–677 (2013).

2. Banerji, S. et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 486, 405–409 (2012).

3. Kunz, M. et al. RNA-seq analysis identifies different transcriptomic types and developmental trajectories of primary melanomas. Oncogene 37, 6136–6151 (2018).

4. Chen, H. et al. A pan-cancer analysis of enhancer expression in nearly 9000 patient samples. Cell 173, 386–399.e12 (2018).

5. Mohammed, H. et al. Progesterone receptor modulates ERα action in breast cancer. Nature 523, 313–317 (2015).

Cited by 192 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Regulation of prostate-specific membrane antigen (PSMA) expression in prostate cancer cells after treatment with dutasteride and lovastatin;Neoplasia;2024-11

2. NSD2 is a requisite subunit of the AR/FOXA1 neo-enhanceosome in promoting prostate tumorigenesis;Nature Genetics;2024-09-09

3. MYBL2 Drives Prostate Cancer Plasticity: Inhibiting Its Transcriptional Target CDK2 for RB1-Deficient Neuroendocrine Prostate Cancer;Cancer Research Communications;2024-09-01

4. Integrative identification of non-coding regulatory regions driving metastatic prostate cancer;Cell Reports;2024-09

5. Design, Synthesis, and Biological Evaluation of Potent EZH2/LSD1 Dual Inhibitors for Prostate Cancer;Journal of Medicinal Chemistry;2024-08-28